On August 20, 2025, a delegation from the Ningbo Clinical Pathology Diagnosis Center visited Zhejiang Tianyuan Biotechnology Co., Ltd. for an inspection and exchange. Company Chairman Huang Bisheng, General Manager Jiao Mingming, and their team warmly received the visiting guests. The two sides held in-depth discussions on topics such as scientific research cooperation, technological innovation, medical diagnosis, and providing health services for the citizens of Ningbo, achieving fruitful results and reaching cooperative intentions.

      Accompanied by Chairman Huang Bisheng, the representatives from the Ningbo Clinical Pathology Diagnosis Center – including Director Zhang Zhe, Deputy Director Liu Yiyu, Director of Molecular Pathology Zhao Ming, Director of Cytopathology Pan Deng, Director of Translational Pathology Zhang Jin, Director of Equipment and Information Department Du Shengfeng, and young researcher Fang Rong – first visited Tianyuan Bio's technology exhibition hall and laboratories. They gained a detailed understanding of the company's business layout, scientific research achievements, and technological innovation capabilities. Inside the exhibition hall, the rich array of exhibits and detailed materials vividly demonstrated Tianyuan Bio's cutting-edge exploration and practical achievements in the field of cell therapy, particularly leaving a deep impression on the visitors with its outstanding accomplishments in immune cell storage, iPS cell technology, cell culture technology, and the HLA matching library.

      During the subsequent symposium, General Manager Jiao Mingming first introduced the company's management and technical expert team, highlighting Tianyuan Bio's advantage in talent aggregation. Subsequently, Chairman Huang Bisheng emphasized the company's exceptional contributions in setting industry standards, particularly the significant meaning of successfully formulating the National Health Commission's group standard for immune function assessment methods.

      Chairman Huang emphasized that Tianyuan Bio consistently adheres to its mission of "Harnessing the Essence of Science to Safeguard Human Health." Through close collaboration with institutions such as Ningbo University, as well as other universities and research organizations, the company has established an integrated development model that combines industry, academia, and research. This approach continuously drives technological innovation and the translation of scientific achievements into practical applications, thereby injecting robust momentum into regional scientific and technological development.

      Director Zhang Zhe of the Ningbo Clinical Pathology Diagnosis Center spoke highly of Tianyuan Bio's scientific research capabilities and developmental accomplishments, fully affirming the company's leading position in the regional technology sector. He pointed out that Tianyuan Bio's technological strengths in fields such as immune assessment and cell therapy align closely with the clinical diagnosis and scientific research needs of the Pathology Center, indicating significant potential for collaboration between the two parties.

       Deputy Director Liu and Director Zhao expressed that by leveraging their complementary advantages, the two sides could engage in comprehensive cooperation across various areas, including early tumor screening, precision diagnosis, personalized treatment, and rehabilitation monitoring. Such collaboration would jointly contribute to enhancing the healthcare standards in Ningbo and make greater contributions to fields such as domestic cancer treatment and clinical diagnosis.

      Following this, researchers from both sides conducted in-depth discussions on cooperative opportunities in areas such as immune function assessment, research and development of cell therapy technologies, and clinical application translation. Preliminary collaborative intentions were successfully established. Moving forward, Tianyuan Bio will join hands with the Ningbo Clinical Pathology Diagnosis Center to advance together, driven by technological innovation and guided by clinical needs. The partnership will focus on accelerating the clinical translation of scientific research outcomes, providing patients with more precise and efficient medical services, and collectively writing a new chapter in the development of the healthcare industry.

Zhejiang Tianyuan Biotechnology Co., Ltd. was established in 2017 and is a national high-tech enterprise dedicated to the research, development, production, operation, and service of cell-related technologies. The company possesses valuable resource banks, including an HLA Umbilical Cord Matching Library, an iPS Seed Cell Bank, and a Cancer Cell Bank. It also serves as the drafting unit for the National Health Commission's Group Standard for immune function assessment methods. In collaboration with the National Health Commission's Research Institute, the company has co-established a Joint Laboratory for Metabolic Immunity Monitoring. Furthermore, it operates key research and service platforms, including the Ningbo Storage Center of the National Stem Cell Transformation Resource Bank and the Achievement Transformation Center of the National Health Commission's Research Institute.